Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BJ 018

X
Drug Profile

BJ 018

Alternative Names: BJ-018

Latest Information Update: 05 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BJ Bioscience
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 05 Jul 2022 BJ 018 is available for licensing in World as of 05 Jul 2022. https://www.bjbioscience.com/en/expand#block-body-2
  • 05 Jul 2022 Preclinical trials in Solid tumours in China (Parenteral), prior to July 2022 (BJ Biosciences pipeline, July 2022)
  • 05 Jul 2022 BJ Bioscience announces intention to file an Investigational New Drug (IND) application for Solid tumours, in the fourth quarter of 2023 (BJ Bioscence pipeline, July 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top